title: Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update.
abstract: Epilepsies occur across the entire age range, and their incidence peaks in the first years of life and in the elderly. Therefore, antiepileptic drugs (AEDs) are commonly used at the extremes of age. Rational prescribing in these age groups requires not only an understanding of the drugs' pharmacodynamic properties, but also careful consideration of potential age-related changes in their pharmacokinetic profile. The present article, which updates a review published in 2006 in this journal, focuses on recent findings on the pharmacokinetics of new-generation AEDs in neonates, infants, children, and the elderly. Significant new information on the pharmacokinetics of new AEDs in the perinatal period has been acquired, particularly for lamotrigine and levetiracetam. As a result of slow maturation of the enzymes involved in glucuronide conjugation, lamotrigine elimination occurs at a particularly slow rate in neonates, and becomes gradually more efficient during the first months of life. In the case of levetiracetam, elimination occurs primarily by renal excretion and is also slow at birth, but drug clearance increases rapidly thereafter and can even double within 1 week. In general, infants older than 2-3 months and children show higher drug clearance (normalized for body weight) than adults. This pattern was confirmed in recent studies that investigated the pediatric pharmacokinetics of several new AEDs, including levetiracetam, rufinamide, stiripentol, and eslicarbazepine acetate. At the other extreme of age, in the elderly, drug clearance is generally reduced compared with younger adults because of less efficient drug-metabolizing activity, decreased renal function, or both. This general pattern, described previously for several AEDs, was confirmed in recent studies on the effect of old age on the clearance of felbamate, levetiracetam, pregabalin, lacosamide, and retigabine. For those drugs which are predominantly eliminated by renal excretion, aging-related pharmacokinetic changes could be predicted by measuring creatinine clearance (CLCR). Overall, most recent findings confirm that age is a major factor influencing the pharmacokinetic profile of AEDs. However, pharmacokinetic variability at any age can be considerable, and the importance of other factors should not be disregarded. These include genetic factors, co-morbidities, and drug interactions, particularly those caused by concomitantly administered AEDs which induce or inhibit drug-metabolizing enzymes.
authors: Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
authors: Domenico
authors: D
authors: Italiano
authors: Emilio
authors: E
authors: Perucca
mesh_terms: D000375:Aging / Q000378:metabolism*; D000927:Anticonvulsants / Q000493:pharmacokinetics*; D006801:Humans; D012640:Seizures / Q000378:metabolism*
chemical_list: D000927:Anticonvulsants
references: Ther Drug Monit. 2004 Jun;26(3):251-7
references: 15167623
references: Br J Clin Pharmacol. 2000 Aug;50(2):135-45
references: 10930965
references: J Clin Pharmacol. 1997 Nov;37(11):1015-20
references: 9505994
references: Epilepsia. 2011 Feb;52(2):248-57
references: 21269291
references: Ther Drug Monit. 2012 Aug;34(4):440-5
references: 22777154
references: Pharmacol Ther. 1987;34(1):129-43
references: 3310043
references: Epilepsia. 2009 Nov;50(11):2355-61
references: 19744111
references: Neurology. 2005 Nov 8;65(9):1370-5
references: 16275822
references: Clin Pharmacol Ther. 2003 Jan;73(1):61-70
references: 12545144
references: Int Rev Neurobiol. 2007;81:299-311
references: 17433933
references: Epilepsy Res. 2009 Jul;85(1):60-4
references: 19272754
references: No To Hattatsu. 1998 Jul;30(4):350-1
references: 9734979
references: Br J Clin Pharmacol. 2011 Jul;72(1):63-76
references: 21306415
references: Neurology. 1997 Apr;48(4):1032-7
references: 9109895
references: Epilepsia. 2008 Jul;49(7):1123-41
references: 18503564
references: Drugs. 2011 Nov 12;71(16):2151-78
references: 22035515
references: Clin Pharmacokinet. 2010 Oct;49(10):661-9
references: 20818832
references: Int J Clin Pharmacol Ther. 2009 Dec;47(12):752-60
references: 19954714
references: Epilepsia. 2009 Nov;50(11):2390-6
references: 19563346
references: Clin Pharmacokinet. 1980 Nov-Dec;5(6):485-527
references: 7002417
references: Exp Gerontol. 2003 Aug;38(8):843-53
references: 12915206
references: Drug Metab Dispos. 2009 Sep;37(9):1841-7
references: 19546240
references: Epilepsia. 1996 Aug;37(8):769-73
references: 8764817
references: Int Rev Neurobiol. 2007;81:183-99
references: 17433924
references: Drugs. 1994 Aug;48(2):153-71
references: 7527321
references: Epilepsy Res. 2007 Apr;74(1):60-9
references: 17270398
references: Clin Pharmacokinet. 2008;47(5):333-41
references: 18399714
references: Brain Dev. 2002 Mar;24(2):95-7
references: 11891100
references: Pediatr Neurol. 2005 Nov;33(5):337-44
references: 16243221
references: Ther Drug Monit. 2007 Dec;29(6):789-94
references: 18043477
references: Br J Clin Pharmacol. 1996 Apr;41(4):325-30
references: 8730979
references: Ther Drug Monit. 2002 Jun;24(3):366-74
references: 12021627
references: Epilepsia. 2001;42 Suppl 4:40-3
references: 11564125
references: Clin Pharmacokinet. 2000 Mar;38(3):191-204
references: 10749516
references: Epilepsia. 2005 Oct;46(10):1621-4
references: 16190933
references: Epilepsy Res. 2005 Mar-Apr;64(1-2):1-11
references: 15823510
references: Clin Pharmacokinet. 2006;45(11):1061-75
references: 17048972
references: Pediatr Res. 2012 Jul;72(1):43-9
references: 22495532
references: Epilepsia. 2007 Nov;48(11):2111-5
references: 17651416
references: Epilepsia. 2004 Nov;45(11):1448-52
references: 15509246
references: Epilepsia. 2011 Feb;52(2):234-42
references: 20887365
references: J Clin Pharmacol. 2008 Apr;48(4):455-63
references: 18296554
references: Pharmacol Rep. 2009 Mar-Apr;61(2):197-216
references: 19443931
references: Epilepsy Res. 2012 Feb;98(2-3):130-4
references: 21944894
references: Pharmacol Res. 2013 Apr;70(1):35-40
references: 23287426
references: J Clin Pharmacol. 2004 Nov;44(11):1290-300
references: 15496647
references: Epilepsia. 2001 Dec;42(12):1574-9
references: 11879369
references: Epilepsy Res. 2007 Sep;76(2-3):140-7
references: 17851036
references: Ther Drug Monit. 2004 Dec;26(6):633-7
references: 15570187
references: Ther Drug Monit. 2012 Aug;34(4):390-7
references: 22743350
references: Clin Pharm. 1987 Jul;6(7):548-64
references: 3319364
references: Epilepsia. 2007 Jun;48(6):1117-22
references: 17442002
references: J Clin Pharmacol. 2008 Aug;48(8):966-77
references: 18508949
references: Br J Clin Pharmacol. 1990 Aug;30(2):253-7
references: 2206786
references: Epilepsia. 2010 Oct;51(10):1954-62
references: 20880232
references: Clin Pharmacokinet. 2005;44(4):407-16
references: 15828853
references: Epilepsia. 2002 Oct;43(10):1157-60
references: 12366729
references: CNS Drugs. 2011 Nov 1;25(11):907-12
references: 22054116
references: J Pediatr. 2011 Jul;159(1):152-154.e3
references: 21592494
references: Expert Rev Neurother. 2010 Jun;10(6):851-60
references: 20518600
references: Clin Pharmacokinet. 1992 Oct;23(4):267-78
references: 1395360
references: Ther Drug Monit. 1999 Apr;21(2):182-90
references: 10217338
references: Clin Pharmacokinet. 2006;45(4):351-63
references: 16584283
references: Seizure. 2004 Dec;13 Suppl 1:S17-23; discussion S24-5
references: 15511682
references: J Pediatr. 2002 Jul;141(1):31-5
references: 12091848
references: Epilepsia. 2000;41 Suppl 9:2-6
references: 11156504
references: Epilepsia. 2008 Jul;49(7):1239-76
references: 18397299
references: N Engl J Med. 2003 Sep 18;349(12):1157-67
references: 13679531
references: Pediatr Neurol. 2004 Oct;31(4):248-53
references: 15464635
references: Ther Drug Monit. 2011 Apr;33(2):214-21
references: 21383651
references: J Clin Pharmacol. 2001 May;41(5):507-14
references: 11361047
references: Ther Drug Monit. 1997 Jun;19(3):252-60
references: 9200763
references: Epilepsia. 2007 Jun;48(6):1111-6
references: 17381438
references: Epilepsia. 2011 Oct;52(10):1905-13
references: 21838791
references: Biol Pharm Bull. 2010;33(7):1176-82
references: 20606310
references: Clin Pharmacol Ther. 1991 Oct;50(4):410-9
references: 1914377
references: Epilepsia. 1999 Apr;40(4):474-9
references: 10219274
references: Epilepsy Res. 2011 Mar;94(1-2):117-20
references: 21282041
references: Pediatr Neurol. 2010 Oct;43(4):231-5
references: 20837299
references: Acta Pharmacol Sin. 2012 Nov;33(11):1417-23
references: 23103620
references: Epilepsia. 2005 May;46(5):775-7
references: 15857447
references: Clin Pharmacol Ther. 2003 Aug;74(2):138-49
references: 12891224
references: Epilepsy Res. 2011 Feb;93(2-3):208-11
references: 21256717
references: Ther Drug Monit. 2001 Dec;23(6):630-5
references: 11802095
references: Epilepsia. 2006 Jun;47(6):1068-9
references: 16822254
references: Epilepsia. 2007 Jul;48(7):1351-9
references: 17573925
references: Eur J Clin Pharmacol. 2008 Mar;64(3):267-73
references: 18157705
references: Epilepsia. 2000 Jun;41(6):709-13
references: 10840403
references: Eur J Clin Pharmacol. 2007 Jul;63(7):687-92
references: 17497143
references: Pharmacotherapy. 1999 Apr;19(4):437-41
references: 10212015
references: Epilepsia. 2013 Jan;54(1):156-64
references: 23157581
references: Epilepsia. 2009 May;50(5):1150-7
references: 19175400
references: Br J Clin Pharmacol. 1996 Dec;42(6):779-81
references: 8971436
references: Pediatr Neurol. 1999 May;20(5):339-44
references: 10371378
references: Br J Clin Pharmacol. 1997 Aug;44(2):129-34
references: 9278196
references: Handb Clin Neurol. 2012;107:113-33
references: 22938966
references: Neuropediatrics. 2012 Oct;43(5):264-70
references: 22941776
references: Clin Pharmacol Ther. 1988 Nov;44(5):558-65
references: 3180638
references: Ther Drug Monit. 2001 Jun;23(3):217-22
references: 11360028
references: Pediatrics. 2008 Jul;122(1):e223-31
references: 18591203
references: Clin Pharmacokinet. 2004;43(11):707-24
references: 15301575
references: Br J Clin Pharmacol. 1997 May;43(5):457-65
references: 9159559
references: Zhongguo Dang Dai Er Ke Za Zhi. 2008 Apr;10(2):105-9
references: 18433522